Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 12/20 | 0.74 |
| ▸ | CDK5R1 | Q15078 | 11/20 | 0.74 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.74 |
| ▸ | CDK2 | P24941 | 7/20 | 0.74 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.74 |
| ▸ | CDK1 | P06493 | 6/20 | 0.73 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.73 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.73 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.73 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.72 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.69 |
| ▸ | GSK3B | P49841 | 1/20 | 0.69 |
| ▸ | MERTK | Q12866 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | CDK4 | P11802 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | PAK4 | O96013 | 1/20 | 0.67 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29444630 | 1.00 | CDK5 (0.74) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL20549706 | 0.89 | CDK5 (0.73) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL5839477 | 0.88 | CDK5 (0.72) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL5749121 | 0.88 | CDK1 (0.70) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL5827777 | 0.88 | CDK5 (0.79) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL21282802 | 0.87 | CDK1 (0.74) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL5839709 | 0.86 | CDK5 (0.69) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL17212873 | 0.85 | CDK5 (1.00) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL28302070 | 0.84 | CDK1 (1.00) | CDK5CDK5R1CCNA2CDK2CCNA1 | |
| SCHEMBL4489273 | 0.84 | CDK5 (0.66) | CDK5CDK5R1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11337981-B2 | Dual CLK/CDK1 inhibitors for cancer treatment | SRI INTERNATIONAL (US) | 2022-05-24 | — | — | US | disclosed |
| US-20200390772-A1 | DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT | SRI INTERNATIONAL | 2020-12-17 | — | — | US | disclosed |
| US-10722515-B2 | Dual CLK/CDK1 inhibitors for cancer treatment | SRI INTERNATIONAL (US) | 2020-07-28 | — | — | US | disclosed |
| US-10722515-B2 | Dual CLK/CDK1 inhibitors for cancer treatment | SRI INTERNATIONAL (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190255059-A1 | DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT | SRI INTERNATIONAL | 2019-08-22 | — | — | US | disclosed |
| US-20190255059-A1 | DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT | SRI INTERNATIONAL | 2019-08-22 | — | — | US | disclosed |
| WO-2018064545-A1 | DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT | SRI INTERNATIONAL (US) | 2018-04-05 | — | — | WO | disclosed |
| US-7091346-B1 | Purine derivatives and processes for their preparation | NOVARTIS AG (CH) | 2006-08-15 | — | — | US | disclosed |
| EP-0874846-B1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2003-04-02 | — | — | EP | disclosed |
| CN-1066147-C | Purine derivatives and process for preparing same | 诺瓦提斯公司 | 2001-05-23 | — | — | CN | disclosed |
| CN-1202896-A | Purine derivatives and processes for their preparation | 诺瓦提斯公司 | 1998-12-23 | — | — | CN | disclosed |
| EP-0874846-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997016452-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11337981-B2 | Dual CLK/CDK1 inhibitors for cancer treatment | CLK2, CLK1, CLK3 | CDK5 40/4885CDK5R1 131/4885CCNA2 294/4885 |
| US-20200390772-A1 | DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT | CLK2, CLK1, CLK3 | CDK5 40/4885CDK5R1 131/4885CCNA2 294/4885 |
| US-10722515-B2 | Dual CLK/CDK1 inhibitors for cancer treatment | CLK2, CLK1, CLK3 | CDK5 40/4885CDK5R1 131/4885CCNA2 294/4885 |
| US-20190255059-A1 | DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT | CLK2, CLK1, CLK3 | CDK5 63/4885CDK5R1 200/4885CCNA2 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.